Online inquiry

IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11889MR)

This product GTTS-WQ11889MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets GUCY2C gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_004963.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2984
UniProt ID P25092
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GUCY2C, MLN-0264(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11889MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ11467MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ5316MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CD20-TCB (2:1)
GTTS-WQ2511MR IVTScrip™ mRNA-Anti-CALCRL, AMG 334(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA AMG 334
GTTS-WQ15584MR IVTScrip™ mRNA-Anti-AXL, UNII-FFX71LCS5T(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA UNII-FFX71LCS5T
GTTS-WQ5224MR IVTScrip™ mRNA-Anti-Factor IX substitute, CB 2679d(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CB 2679d
GTTS-WQ12049MR IVTScrip™ mRNA-Anti-NRP1, MNRP1685A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MNRP1685A
GTTS-WQ15939MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ5890MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA CIFN
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW